Skip to Content Skip to Footer
Sunil Prabhu, BPharm, PhD

Sunil Prabhu, BPharm, PhD

Dean and Professor, Biotechnology and Pharmaceutical Sciences

College of Pharmacy

Phone: 909-469-5550

  • Education

    Management Development Program, Harvard Graduate School of Education (HGSE), June 2023

    Academic Leadership Certification, Haas School of Business, University of California, Berkeley, 2012

    AACP Fellow, Academic Leaders Fellowship Program (ALFP), 2009

    Doctor of Philosophy (PhD), Pharmaceutics, 1996
    West Virginia University, Morgantown, WV

    Bachelor of Pharmacy (B.Pharm)1987
    Birla Institute of Technology, India

  • Research Interest

    Formulation development of novel drug delivery systems; application of nanotechnology
    for controlled release system design; cancer chemoprevention; targeted therapy.

  • Research Grant

    Principal Investigator, “Combinatorial nanotechnology-based regimens for pancreatic cancer chemoprevention” NIH, National Cancer Institute (NCI), R15 program, 2014-2017.

    Principal Investigator, “Chemoprevention of pancreatic cancer using a combinatorial nano-drug system” NIH, National Cancer Institute (NCI), R03 program, 2011-2013.

    Principal Investigator, "Combined Chemoprevention Using A Nanotechnology-based Therapeutic System", NIH, National Cancer Institute (NCI), R03 Program, 2007- 2010.

  • Publications

    Thakkar A, Chenreddy S, Wang J, Prabhu S. “Evaluation of Ibuprofen loaded solid lipid nanoparticles and its combination regimens for pancreatic cancer chemoprevention” Int J. Onc., accepted, January 2015.

    L. Luo, J. Lacroix, S. Prabhu, “Antibody-Drug Conjugates: The 21st Century Magic Bullets for Cancer." Case Studies: Ado-Trastuzumab Emtansine. AAPS-Springer, In press, January 2015.

    Liu M, Ravula R, Wang Z, Zuo Z, Chow M, Thakkar A, Prabhu S, Andresen B, Huang Y. “Traditional Chinese medicinal formula Si-Wu-Tang prevents oxidative damage by activating Nrf2-mediated detoxifying/antioxidant genes.” Cell & Bioscience. 2014; 4(1):8. PubMed PMID: doi:10.1186/2045-3701-4-8.

    Grandhi BK, Thakkar A, Wang J, Prabhu S. “A novel combinatorial nanotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions” Cancer Prev Res., 6 (10), 1015 – 1025, 2013.

    A. Thakkar, D. Sutaria, B.K. Grandhi, J. Wang, S. Prabhu, “The molecular mechanisms of action of aspirin, curcumin and sulforaphane combinations in the chemoprevention of pancreatic cancer” Onc. Reports, 29, 4, 1671-1677, 2013.

    D. Sutaria, B. K. Grandhi, A. Thakkar, J. Wang and S. Prabhu, “Chemoprevention of pancreatic cancer using solid-lipid nanoparticulate delivery of a novel aspirin, curcumin and sulforaphane (ACS) drug combination regimen”, 41(6):2260 – 2268, Int J Onc, 2012.

    A. Chaudhary, D. Sutaria, Ying Huang, J. Wang and S. Prabhu. “Chemoprevention of Colon Cancer in a Rat Carcinogenesis Model using a Novel Nanotechnology-based Combined Treatment System”. Cancer Prev. Res., 4(10), 1655-1664, 2011.

    Prabhu S, Y Huang, Wang J. Evidence-based materia medica for cancer chemoprevention. In: Evidence-based Anticancer Complementary and Alternative Medicine2: Materia Medica for Various Cancers. Cho WCS (Ed), Springer, 2011, 315-351.

    C. Ma, S. Prabhu, “Characterization of a novel lyophilized chitosan hydrogel complex for the controlled release of a highly water soluble drug, niacinamide.” Int. J. Drug Del. 3 (1):55-63, 2011.